Thyquidity - (100 mcg/5 mL; Oral solution)

Generic Name	Levothyroxine Sodium	Innovator	Azurity (Arbor)
Dosage	100 mcg/5 mL; Oral solution	Branded US Sales	Less Than $1000 mn
Probable FTF	Less Than 5	Known Para IV Filers	Less Than 5
Other ANDA developers	Less Than 5	Tentative Approvals	None
Final Approvals	None	Generic Launches	None
Indication	THYQUIDITY is levothyroxine sodium (T4) indicated for: 1)Hypothyroidism - As replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism. 2) Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression - As an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer
Complexities	Yes

Executive Summary

Patent Status

Launch Timelines and Competition

Company	FTF Status / 180 days exclusivity	30-Months stay	Current Litigation Status	Current Approval Status	Likelihood of launch
****** (*****)	*** \ *********	*** **, ****	********* ** ****** ** ******	****	******* *** **** *** *** ****

Chronology Of Events